What Evidence Shows About Ozempic and Gastroparesis Risk
Latest update (2026-01)
- FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Information to Specific Risk Awareness
If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder whether the medication could be causing gastroparesis. This concern has grown as more patients report symptoms of delayed gastric emptying. Building on decades of research into GLP-1 receptor agonists, this page examines what current evidence can and cannot prove about the connection between Ozempic and gastroparesis.
Understanding Gastroparesis and Its Link to Ozempic
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology involves stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. The latter effect is central to its therapeutic action but also underlies many of its gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanistic pathway linking Ozempic to gastroparesis involves its effect on gastric motility. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone. While this effect is intended to improve glycemic control, it can become pathological in susceptible individuals, leading to symptomatic gastroparesis.
Clinical Evidence and Adverse Reaction Data
The reported adverse reactions in clinical trials include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and persistent cases may represent drug-induced gastroparesis. Regarding the adequacy of warnings, the prescribing information for Ozempic includes a section on gastrointestinal adverse reactions but does not explicitly list gastroparesis as a warning or precaution. The label notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be relevant in evaluating whether the manufacturer provided adequate notice of this risk. Patients who developed gastroparesis after using Ozempic may argue that the warnings were insufficient to alert them or their healthcare providers to the potential for this serious adverse effect.
Statute of Limitations for Ozempic Claims in Massachusetts
Settlement-related considerations for affected patients in Massachusetts involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient first experiences symptoms that lead to a diagnosis or when a reasonable person would have connected the symptoms to the drug. The timeline between exposure and documented harm is critical: patients may have used Ozempic for months or years before developing gastroparesis, and the diagnosis may occur after discontinuation. Delayed recognition of the link between the drug and the condition can complicate the statute of limitations analysis. Massachusetts courts apply a "discovery rule" that may extend the filing deadline if the injury was not immediately apparent. However, patients should consult with an attorney promptly to assess their specific circumstances, as delays can jeopardize their ability to seek compensation. In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions that can include symptoms consistent with gastroparesis. The mechanistic plausibility is supported by the drug's effect on gastric emptying. The adequacy of warnings is questionable given the lack of explicit mention of gastroparesis. For Massachusetts patients, the statute of limitations is a key factor in any potential settlement or litigation, and timely legal advice is essential.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Ozempic-related gastroparesis claims in Massachusetts?
In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis allegedly caused by Ozempic, the clock typically starts when the patient first experiences symptoms that lead to a diagnosis or when a reasonable person would have connected the symptoms to the drug. Delayed recognition may extend the deadline under the discovery rule, but prompt legal consultation is advised.
Does Ozempic's prescribing information warn about gastroparesis?
The prescribing information for Ozempic includes a section on gastrointestinal adverse reactions but does not explicitly list gastroparesis as a warning or precaution. The label notes serious hypersensitivity reactions and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific warning for gastroparesis may be relevant in evaluating whether the manufacturer provided adequate notice of this risk.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Is Gastroparesis from Ozempic permanent
- Statute of limitations for Ozempic in Ohio
- Statute of limitations for Ozempic in Illinois
- Washington Ozempic Gastroparesis injury lawyer
- Ozempic Gastroparesis lawsuit settlement criteria
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.